IRVINE, CA / ACCESSWIRE / March 20, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Roadrunner Transportation Systems Inc. (“Roadrunner” or the “Company”) (NYSE: RRTS). Investors, who purchased or otherwise acquired Roadrunner shares between May 8, 2014 and January 30, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the April 03, 2017 lead plaintiff deadline.

If you purchased shares of Roadrunner during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

Roadrunner revealed on January 30, 2017 that its financial statements would need to be reissued. The Company revealed a few accounting mistakes that it anticipates will necessitate changes of $20 million to $25 million. The Company mentioned that it is currently being investigated.

When this information was released to the public, the value of Roadrunner fell, causing investors harm.

If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457719

IRVINE, CA / ACCESSWIRE / March 20, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against ReWalk Robotics Ltd. (“Rewalk” or the “Company”) (NASDAQ: RWLK). Investors, who purchased or otherwise acquired Rewalk shares pursuant and/or traceable to the Company’s Stock Offering on or about September 12, 2014, are encouraged to contact the firm in advance of the March 27, 2017 lead plaintiff motion deadline.

If you purchased shares of ReWalk during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

The Complaint alleges that the Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a postmarket surveillance study. When this information was announced to the public, the value of Rewalk fell, causing investors serious harm.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457723

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Lifeloc Technologies, Inc. (OTC PINK: LCTC), a global leader in portable breath alcohol testing devices, announced today that CEO, Dr. Wayne Willkomm, will be presenting at this year’s MicroCap Conference on April 4th in New York City.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

SOURCE: Lifeloc Technologies, Inc.

ReleaseID: 457722

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against The Toronto-Dominion Bank (“TD” or the “Company”) (NYSE: TD) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased TD securities between December 3, 2015 through March 9, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/td.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed that: (1) TD’s wealth asset growth and increased fee-based revenue was spurred by a performance management system that steered to its employees breaking the law at their customer’s expense in order to meet sales targets; (2) TD illegitimately increased customer’s lines of credit and overdraft protection amounts without their knowledge; (3) TD illegitimately upgraded customers to higher-fee accounts without informing them; (4) TD lied to customers as to the risk of its products; and (5) consequently, defendants’ statements about TD’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On March 10, 2017, CBC News reported about the pressures put on TD Bank branch employees to sign up customers for products they don’t need. The report said that current and former TD employees described a pressure cooker environment that has “zero focus on ethics.” Following this news, TD stock dropped during intraday trading on March 10, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/td, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 457515

IRVINE, CA / ACCESSWIRE / March 20, 2017 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against NantHealth, Inc. (“NantHealth” or the “Company”) (NASDAQ: NH). Investors, who purchased or otherwise acquired NantHealth shares between February 19, 2013 and March 1, 2017, inclusive (the “Class Period”), are encouraged to contact the firm in advance of the May 2, 2017 lead plaintiff deadline.

If you purchased shares of NantHealth during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

STAT, a news organization centered on medical industry reporting, published an article claiming that NantHealth founder, Patrick Soon-Shiong, had conferred $12 million to the University of Utah through tax-exempt entities that he controlled.

The contract necessitated the University to expend most of these funds into NantHealth. STAT claims the plan allowed the Company to falsely inflate the number of test orders it reported to shareholders. When this information was offered to the investing public, NantHealth stock dropped, causing investors harm.

If you wish to learn more about this lawsuit, at no charge, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contact:

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 457589

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Levi & Korsinsky announces it has commenced an investigation of MRC Global Inc. (NYSE: MRC) concerning possible breaches of fiduciary duty. To obtain additional information, go to:

http://zlk.9nl.com/mrc-global

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

Levi & Korsinsky is a national firm with offices in New York, Connecticut, California, and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities lawsuits and have recovered hundreds of millions of dollars for aggrieved shareholders. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 457725

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against ReWalk Robotics Ltd. (“ReWalk” or the “Company”) (NASDAQ: RWLK) and certain of its officers, on behalf of a class who purchased ReWalk securities pursuant to the Company’s initial public offering (“IPO”) on or around September 12, 2014. Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/rwlk.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

ReWalk is a medical commercial bionic walking assistance system. The Company designs, develops, and commercializes exoskeletons for wheelchair-bound individuals.

The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements in its Registration Statement and Prospectus issued in regards with the Initial Public Offering did not disclose material information, including that ReWalk could not comply with “special controls” requirements or to offer the U.S. Food and Drug Administration with a post market surveillance study. Once this information was made public, ReWalk stock price dropped, causing investors harm.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: http://www.bgandg.com/rwlk, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in ReWalk, you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454432

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Hooper Holmes Inc.’s (NYSE: HH) CEO, Henry E. Dubois, will be a featured presenter at the MicroCap Conference on April 4th in New York City. Mr. Dubois will be available for one-on-one investor meetings throughout the conference.

CONFERENCE OVERVIEW AND STRUCTURE

The MicroCap Conference is an exclusive event for investors who specialize in small and microcap stocks. It is an opportunity to be introduced to and speak with management at some of the most attractive small companies, learn from various expert panels, and mingle with other investors.

The MicroCap Conference will take place in New York City at the Essex House on April 4th. Registration will begin on Tuesday, April 4th, at 7:00AM, and the event ends with a reception in the evening. The day will be jam-packed with company presentations, one-on-one meetings, good food, and plenty of time to network with other investors over drinks at the reception. This event does not allow service providers – only portfolio managers, analysts, and private investors.

REGISTRATION FOR INVESTORS

To register, please go to our website (www.microcapconf.com) and click “Register.”

PARTICIPATING COMPANIES

For our most updated list of companies, please go to our website (http://microcapconf.com/conferences/new-york-2017/).

MARQUEE SPONSORS

The Special Equities Group
Maxim Group

About Hooper Holmes Inc.

Hooper Holmes mobilizes a national network of health professionals to provide on-site health screenings, laboratory testing, risk assessment, and sample collection services to wellness and disease management companies, employers and brokers, government organizations, and academic institutions nationwide. Under the Accountable Health Solutions brand, the Company combines smart technology, healthcare and behavior change expertise to offer comprehensive health and wellness programs that improve health, increase efficiencies, and reduce healthcare delivery costs (www.hooperholmes.com).

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Tony Yu at tony@microcapconf.com.

For further information:

Hooper Holmes
Henry E. Dubois
President and CEO
(913) 764-1045

Investors: Andrew Berger
S.M. Berger & Company
(216) 464-6400

Investors: Scott Gordon
CORE IR
(516) 222-2560

SOURCE: Hooper Holmes Inc.

ReleaseID: 457720

NEW YORK, NY / ACCESSWIRE / March 20, 2017 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Psychemedics Corporation (“Psychemedics” or the “Company”) (NASDAQ: PMD) and certain of its officers, on behalf of a class who purchased Psychemedics securities between February 28, 2014 and January 30, 2017, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/pmd.

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) through its affiliate, Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics engaged in anticompetitive conduct to maintain a monopoly over the Brazilian market in violation of the law; (2) effectively, Psychemedics lacked effective internal controls over financial reporting; and (3) consequently, Psychemedics’ public statements were materially false and misleading at all relevant times.

On January 31, 2017, it was revealed that Psychemedics Brasil Exames Toxicologicos Ltda., Psychemedics’ local representative in Brazil, was ordered to compensate Omega Laboratories, Inc. USA for losses caused by anticompetitive practices used for “preventing other companies from accessing (the) market.” Following this news, Psychemedics stock dropped during intra-trading on January 31, 2017.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: www.bgandg.com/pmd, or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Psychemedics, you have until April 3, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC

Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 454541